ISLT News Alert One E-Commerce Corp (ISLT) 0.1800 10/15/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
One E-Commerce Corp (ISLT) 0.1800 $ISLT

Islet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin Etabonate
GlobeNewswire - Mon Oct 06, 7:10AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, announced that its merger partner, BHV Pharma, has entered into an exclusive licensing agreement for its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate ("remogliflozin" with Libbs Farmaceutica ("Libbs" , a leading Brazilian pharmaceutical company. Libbs will have exclusive rights to develop and commercialize remogliflozin in select territories in Latin America, including Brazil.

Islet Sciences and BHV Pharma Enter Into Merger Agreement; Combined Company to be Named Avogenx, Inc.
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Islet Sciences, Inc. (OTCQB:ISLT) ("Islet Sciences" , a biopharmaceutical company developing new medicines and technologies for the treatment of metabolic disease, and Brighthaven Ventures, L.L.C., d/b/a BHV Pharma ("BHV" , a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" , jointly announced today that, consistent with the letter of intent entered into by Islet Sciences and BHV on March 12, 2014, they have entered into a merger agreement that will combine the operations and development pipelines of the two companies. Upon closing of the acquisition of BHV, the combined organization will be named Avogenx, Inc. ("Avogenx" and will continue to operate under the leadership of the current Islet Sciences management.

Islet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 Inhibitors
GlobeNewswire - Wed Aug 06, 7:00AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application titled, "Lisofylline Analogs and Methods for Use." The new patent (U.S #13/477,613) will extend coverage to include a significantly broader gamut of chemical compounds, which Islet may develop as immune-modulating drugs targeting an inflammatory pathway involved in a number important diseases, including diabetes and nonalcoholic steatohepatitis (NASH).

Islet Sciences, Inc. Announces Peer-Reviewed Publication of Study Validating Novel Diabetes Diagnostic
GlobeNewswire - Wed Jul 16, 7:23AM CDT
Islet Sciences, Inc. (OTCQB:ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, announced today that its collaborators at the Yale University School of Medicine have published key data highlighting the efficacy of Islet's novel diabetes diagnostic in Endocrinology, the journal of the Endocrine Society. The study demonstrated improved detection of beta-cell loss, a key biomarker of diabetes progression, using a novel technology called droplet digital PCR (ddPCR).

Islet Sciences, Inc. Highlights Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)
PR Newswire - Mon Jun 23, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, recently presented a peer-reviewed poster highlighting the unique properties of its selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), as a novel treatment for non-alcoholic steatohepatitis (NASH) and its precursor, non-alcoholic fatty liver disease (NAFLD). The poster was presented this past Saturday at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.

Islet Sciences, Inc. to Present at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014
PR Newswire - Wed Jun 18, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, will present a peer-reviewed poster relating to its highly selective sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate (a prodrug of active remogliflozin), at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society, at the McCormick Place West in Chicago, IL, June 21-24.

Islet Sciences, Inc. Presents Positive Clinical Results for Best-in-Class SGLT2 Inhibitor at American Diabetes Association (ADA) Annual Meeting
PR Newswire - Mon Jun 16, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing new medicines and technologies for the treatment and diagnosis of metabolic disease, presented final results from its two Phase 2b clinical studies evaluating remogliflozin etabonate (a prodrug of remogliflozin, the active inhibitor) at the 74th American Diabetes Association (ADA) Annual Scientific Sessions, showing that the differentiated sodium glucose co-transporter 2 (SGLT2) inhibitor demonstrated a potential best-in-class safety and efficacy profile, when dosed once-daily or twice-daily, respectively. Positive Phase 1 results were also presented for the company's novel once-daily biphasic formulation of remogliflozin etabonate, which achieved targeted pharmacokinetic and pharmacodynamic profiles, successfully combining the best-in-class properties of previous formulations.

Islet Sciences, Inc. to Present at American Diabetes Association (ADA)
PR Newswire - Thu Jun 12, 7:00AM CDT
Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the treatment and diagnosis of metabolic disease, announced today it will present three peer-reviewed posters relating to its differentiated sodium glucose transporter 2 (SGLT2) inhibitor, remogliflozin etabonate, at the 74th American Diabetes Association (ADA) Scientific Sessions at the Moscone Center in San Francisco, June 13-17.

Islet Sciences to Host Conference Call to Discuss Acquisition of BHV Pharma
Marketwire - Mon Mar 17, 8:30AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced that on Monday, March 17, 2014, the Company will host a conference call to discuss the announced acquisition of BHV Pharma. The call is scheduled to take place at 4:15 p.m. ET.

Islet Sciences appoints Dr. Michael Luther to board
M2 - Mon Mar 17, 7:55AM CDT
US-based biopharmaceutical company Islet Sciences (OTCQB:ISLT) revealed on Friday the addition of Dr. Michael Luther to its board of directors.
AMRI: 20.27 (-0.45)

Islet Sciences Appoints Michael Luther, Ph.D., MBA to Board of Directors
Marketwire - Fri Mar 14, 8:10AM CDT
Islet Sciences, Inc. (OTCQB: ISLT) today announced the appointment of Dr. Michael Luther, Senior Vice President of Discovery and Development at Albany Molecular Research, Inc. to Islet's Board of Directors.
AMRI: 20.27 (-0.45)

Islet Sciences to buy BHV Pharma, including Phase two SGLT2 inhibitor remogliflozin etabonate for Type 2 diabetes and NASH
M2 - Fri Mar 14, 4:10AM CDT
Biopharmaceutical company Islet Sciences (OTCBB:ISLT) (OTCQB:ISLT) said on Thursday that it has entered into a binding letter of intent to acquire Brighthaven Ventures /BHV Pharma (BHV), including the remogliflozin programme.

Islet Sciences to Acquire BHV Pharma and Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate Indicated for Type 2 Diabetes and NASH
Marketwire - Thu Mar 13, 8:15AM CDT
Islet Sciences, Inc. (OTCBB: ISLT) (OTCQB: ISLT) today announced that it has signed a binding letter of intent to acquire Brighthaven Ventures, LLC d/b/a BHV Pharma ("BHV" . BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate ("remogliflozin" for type 2 diabetes and non-alcoholic steatohepatitis ("NASH" . Remogliflozin is currently in phase 2 clinical development.

CORWIL Technology Corporation Completes Asset Purchase Of VIKO Test Labs
PR Newswire - Mon Mar 10, 10:01PM CDT
CORWIL Technology Corporation ("CORWIL" has announced the asset purchase of VIKO Test Labs, a division of Infiniti Solutions. The addition of electrical, environmental, and mechanical test services enhances CORWIL's market position as a true OSAT (Outsourced Semiconductor Assembly & Test) leader, joining an exclusive list of domestic providers with both assembly and test operations located in the United States.

Islet Holdings Files Amended Complaint Against Islet Sciences
GlobeNewswire - Fri Aug 02, 2:56PM CDT
According to Islet Holdings, new allegations of conspiracy and racketeering and a written confession from a scheme participant have led to the resignation of CEO John Steel and the restructuring of the management team at Islet Sciences, Inc. (OTCBB:ISLT). The restructuring was announced after an amended complaint was filed in federal court charging that Islet Sciences has been enticing investments using false documents, and that Steel has "made numerous threats against anyone related to Isletech."

Islet Sciences Begins Restructuring of Company's Senior Management and Board of Directors
Business Wire - Tue Jul 16, 3:51PM CDT
Islet Sciences, Inc., (OTCBB:ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, today announced changes to the company's senior management team and the board of directors.

Islet Sciences Chief Scientific Officer to Present Scientific Studies at Upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy
Business Wire - Mon Jul 08, 8:44AM CDT
Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today that Dr. Jonathan Lakey, Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine and Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences, will be presenting several scientific presentations at the upcoming 12th Congress of the Cell Transplant Society (CTS) in Milan, Italy July 7-11, 2013.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 90

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 106

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 9

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 76

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 189

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 133

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from BioRestorative's CEO on Regenerative Medicine

Updated Category News Views 168

CEO Lance Alstodt Discusses BioRestorative's Vision In a recent interview on “The Big Biz Show,” the dynamic CEO of BioRestorative Therapies, Inc., Lance Alstodt, shared invaluable insights into the company's journey. As a pioneer in regenerative medicine, BioRestorative focuses on innovative stem cell-based therapies aimed at addressing various medical challenges....

Continue Reading
Hargreave Hale AIM VCT PLC NAV Announcement

Updated Category News Views 73

Hargreave Hale AIM VCT PLC (the “Company”) Net Asset Value Announcement As of the close of business on 16 August 2024, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc stands at: NAV per Ordinary share of 1p – 42.03 pence. Contact Information If you need more information, please reach out to: JTC (UK) Limited Uloma Adighibe Alexandria Tivey Email...

Continue Reading
Discover Luxury Living at Toll Brothers' New Community in Texas

Updated Category News Views 150

Introducing Toll Brothers at George's Ranch In a splendid showcase of luxury living, Toll Brothers, Inc. (NYSE:TOL) has unveiled its newest community, Toll Brothers at George's Ranch, located in the serene surroundings of Boerne, Texas. This exciting development marks an important addition to the San Antonio area, where elegance meets modern design. Grand Opening...

Continue Reading
xLean's TR1 Robot Revolutionizes Cleaning Technology

Updated Category News Views 224

xLean's Innovative TR1 Takes Center Stage xLean Robotics concluded an exciting showcase at IFA 2025, where its groundbreaking TR1, the world's first dual-form transformable floor washing robot, earned several prestigious awards. This innovative device was recognized as the 'Best in IFA Next Winner' and 'Best in Design Honoree,' and it was featured as one of the 'Top 5...

Continue Reading
Alpha Modus Sues H&M for Patent Infringement Regarding AI Tech

Updated Category News Views 165

Alpha Modus Files Patent Infringement Lawsuit Against H&M Alpha Modus, Corp. is making headlines for filing a substantial patent infringement lawsuit against H&M Fashion USA, Inc. in the United States District Court for the Eastern District of Texas, Marshall Division. This legal action centers around allegations that H&M's retail operations in the U.S. are infringing...

Continue Reading